Valuation: Xspray Pharma AB

Market Cap 654M 68.79M 59.61M 55.81M 50.92M 95.82M 6.56B 97.43M 256M 3.28B 258M 253M 10.96B P/E 2026 *
-2.23x
P/E 2027 * 4.18x
Enterprise Value 654M 68.79M 59.61M 55.81M 50.92M 95.82M 6.56B 97.43M 256M 3.28B 258M 253M 10.96B EV / Sales 2026 *
33.9x
EV / Sales 2027 * 1.16x
Free-Float
85.26%
Yield 2026 *
-
Yield 2027 * -
1 day-3.77%
1 week-14.71%
Current month-18.25%
1 month-7.63%
3 months-42.14%
6 months-42.74%
Current year-56.12%
1 week 13.54
Extreme 13.54
16.8
1 month 13.54
Extreme 13.54
17.24
Current year 13.54
Extreme 13.54
32.5
1 year 13.54
Extreme 13.54
64.1
3 years 13.54
Extreme 13.54
91.7
5 years 13.54
Extreme 13.54
147.2
10 years 13.54
Extreme 13.54
267
Manager TitleAgeSince
Chief Executive Officer - 2026-05-31
Director of Finance/CFO 34 -
Chief Tech/Sci/R&D Officer 73 2022-12-31
Director TitleAgeSince
Director/Board Member 70 2014-12-31
Director/Board Member 52 2018-12-31
Chairman 72 2022-05-18
Date Insider Type Main position Quantity % Market Cap.
4/22/26 Sell

Director

4 0.0000%
4/22/26 Buy

Director

810 0.0019%
9/19/25 Buy

Director

2,063 -
Change 5-day change 1-year change 3-year change Capi.($)
-3.77%-14.71%-72.09%-56.88% 71.66M
-0.70%+24.68%+76.72%+103.05% 70.85B
-2.35%+3.71%+31.77%+63.89% 55.41B
-1.62%+34.66%+21.01%+483.49% 29.43B
-0.30%+18.51%+56.61%+4.86% 24.12B
0.00%+0.60%-16.89%-12.00% 23.31B
+0.05%+7.96%+44.21%-22.57% 18.37B
+9.77%+25.32%+252.40%+442.16% 16.99B
0.00%+10.84%+31.14%+628.97% 16.1B
-3.08%-6.77%+36.08%+142.70% 13.12B
Average -0.20%+353.77%+46.10%+177.77% 26.78B
Weighted average by Cap. -0.41%+349.80%+55.48%+164.32%

Financials

2026 *2027 *
Net sales 19.3M 2.03M 1.76M 1.65M 1.5M 2.83M 194M 2.87M 7.56M 96.86M 7.62M 7.45M 323M 564M 59.29M 51.38M 48.1M 43.89M 82.59M 5.65B 83.98M 221M 2.83B 223M 218M 9.44B
Net income - -
Net Debt - -
Logo Xspray Pharma AB
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
Employees
24
Date Price Change Volume
26-08-11 SEK 13.80 -3.77% 132,818
26-08-10 SEK 14.34 -4.53% 133,638
26-08-07 SEK 15.02 +2.04% 103,473
26-08-06 SEK 14.72 -4.66% 87,646
26-08-05 SEK 15.44 -6.99% 220,783

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XSPRAY Stock